Patents by Inventor Daniela FLIEGNER

Daniela FLIEGNER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR
    Publication number: 20190367516
    Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: August 13, 2019
    Publication date: December 5, 2019
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexander STRAUB, Markus BRECHMANN, Thomas MÜLLER, Mark MEININGHAUS, Katrin NOWAK-REPPEL, Hanna TINEL, Klaus MÜNTER, Daniela FLIEGNER, Thomas MONDRITZKI, Melissa BOULTADAKIS ARAPINIS, Tobias MARQUARDT, Alexandros VAKALOPOULOS, Anne-Sophie REBSTOCK, Matthias Beat WITTWER
  • Positive allosteric modulators of muscarinic M2 receptor
    Patent number: 10435403
    Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 8, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Henrik Teller, Alexander Straub, Markus Brechmann, Thomas Müller, Mark Meininghaus, Katrin Nowak-Reppel, Hanna Tinel, Klaus Münter, Daniela Fliegner, Thomas Mondritzki, Melissa Boultadakis Arapinis, Tobias Marquardt, Alexandros Vakalopoulos, Anne-Sophie Rebstock, Matthias Beat Wittwer
  • POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR
    Publication number: 20180297994
    Abstract: The present application relates to positive allosteric modulators of the muscarinic M2 receptor, especially to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular disorders and/or renal disorders.
    Type: Application
    Filed: June 6, 2016
    Publication date: October 18, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Henrik TELLER, Alexander STRAUB, Markus BRECHMANN, Thomas MÜLLER, Mark MEININGHAUS, Katrin NOWAK-REPPEL, Hanna TINEL, Klaus MÜNTER, Daniela FLIEGNER, Thomas MONDRITZKI, Melissa BOULTADAKIS ARAPINIS, Tobias MARQUARDT, Alexandros VAKALOPOULOS, Anne-Sophie REBSTOCK, Matthias Beat WITTWER